Research Technologies
Genentech as part of the Roche Group is at the forefront when it comes to collaboration with biotechs at all development stages to drive the application of technology and modality platforms that have the potential to transform discovery as well as generate innovative medicines beyond the standard of care.
Partnering opportunities we are looking for:
- New mechanism of actions and enabling technologies to expand the druggable target space (across therapeutic modalities)
- Targeted delivery
- Genomic Medicine platforms
- Novel target discovery
- ML-enabled drug discovery
Example partnerships
Arrakis Therapeutics – Research collaboration to discover and develop RNA-targeted small molecules against a broad set of targets across Roche’s R&D areas
Bicycle Therapeutics – Research collaboration to discover and develop immunomodulatory bicyclic peptides for the treatment of cancer
NVIDIA – Partnership to accelerate R&D by using AI and computing technology to better understand disease biology and develop novel therapeutics
Orionis Biosciences – Collaboration to discover and develop novel small molecule medicines, including molecular glues, for challenging targets in major disease areas, including oncology and neurodegeneration
Recursion – Research collaboration with Roche and Genentech to use machine learning and high content screening methods at scale to map complex biology in neuroscience and oncology
Sangamo Therapeutics – Global epigenetic regulation and capsid delivery license agreement to develop novel genomic medicines for neurodegenerative diseases
Shape Therapeutics – Research collaboration to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications
Skyhawk Therapeutics – research collaboration to discover and develop small molecule RNA splicing modifiers for oncology and neurodegenerative diseases
Vividion Therapeutics – Research collaboration to discover and develop compounds targeting novel E3 ligases and a range of oncology and immunology therapeutic targets based on Vividion’s covalent chemistry
Your dedicated partnering leads in Research Technologies
Barbara Lueckel, Head of Research Technologies, Pharma Partnering
Tomas Hejhal, Search & Evaluation Lead Research Technologies, Pharma Partnering